Clinical Cancer Research

Table of Contents

January 1, 2015 • Volume 21 • Number 1

Highlights of This Issue 1

SPECIAL FEATURES

CCR 20th Anniversary Commentary

3 Clinical Cancer Research: The 20th Anniversary

CCR Translations

4 Bromodomain Inhibition in Diffuse Large B-cell Lymphoma—Giving MYC a Brake
   Anja Mottok and Randy D. Gascoyne
   See related article, p. 113

7 New, Tolerable γ-Secretase Inhibitor Takes Desmoid Down a Notch
   Dennis P. M. Hughes, Shivaani Kummar, and Alexander J. Lazar
   See related article, p. 60

CCR New Strategies

10 New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease
   Ramaprasad Srinivasan, Christopher J. Ricketts, Carole Sourbier, and W. Marston Linehan

Molecular Pathways

18 Molecular Pathways: Not a Simple Tube—The Many Functions of Blood Vessels
   Brent A. Orr and Charles G. Eberhart

24 Molecular Pathways: Targeting the Kinase Effectors of RHO-Family GTPases
   Tatiana Y. Prudnikova, Sonali J. Rawat, and Jonathan Chernoff

CANCER THERAPY: CLINICAL

30 Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma
   Joseph A. Califano, Zubair Khan, Kimberly A. Noonan, Lakshmi Rudraraju, Zhe Zhang, Hao Wang,
   Steven Goodman, Christine G. Gouzin, Patrick K. Ha, Carole Fakhry, John Saunders, Marshall Levine, Mei Tang,
   Geoffrey Neuner, Jeremy D. Richmon, Ray Blanco, Nishant Agrawal, Wayne M. Koch, Shanthi Marur,
   Donald T. Weed, Paolo Serafini, and Ivan Borrello

39 Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma
   Donald T. Weed, Jennifer L. Vella, Isidirnha M. Reis, Adriana C. De la fuente, Carmen Gomez, Zuokaa Sargi,
   Ronen Nazarian, Joseph Califano, Ivan Borrello, and Paolo Serafini

49 Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial
   Serena Di Cosimo, Sitirom Sadharamaryanan, Johanna C. Bendell, Andreas Cervantes, Mark N. Stein,
   Irene Briata, Desamparados Rona, Brian E. Haines, Theresa Zhang, Christopher G. Winter, Sharda Iha,
   Youyuuan Xu, Jason Frazier, Richard A. Klinghofer, Ann Leighdon-Swayne, Yang Song, Scot Ebbinghaus, and Jose Baselga

60 A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014
   Wells A. Messersmith, Geoffrey I. Shapiro, James M. Cleary, Antonio Jimeno, Avind Dasari,
   Bo Huang, M. Naved Shah, Rossano Cesari, Xianxian Zheng, Jennifer M. Reynolds,
   See related commentary, p. 7

68 A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis
   Kim A. Reiss, Joseph M. Herman, Marianna Zahurak, Anthony Brade, Laura A. Dawson, Angelica Scardina,
   Caitlin Joffe, Emily Petitot, Amy Hacker-Prietz, Robert J. Kinders, Lihua Wang, Alice Chen,
   Sarah Temkin, Naomi Horiba, Lillian L. Siu, and Nilofar S. Azad

77 First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
   Debasish Sarker, Joo Em Ang, Richard Baird, Rebecca Kiesleli, Krunal Shah, Victor Moreno,
   Paul A. Clarke, Florence J. Raynald, Gallia Levy, Joseph A. Ware, Kathryn Mazina, Ray Lin, Jenny Wu,
   Jill Fredericksen, Jill M. Spoerke, Mark R. Lackner, Yibing Yan, Lori S. Friedman, Stan B. Kaye,
   Miha Derynck, Paul Workman, and Johann S. de Bono
# Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Article</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>87</td>
<td>First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors</td>
<td>Geoffrey I. Shapiro, Eunice Kwak, Bruce J. Dezube, Murray Yule, John Ayrton, John Lyons, and Danuka Mahadevan</td>
</tr>
<tr>
<td>106</td>
<td>Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessment of Antiangiogenic Treatment Effects in Multiple Myeloma</td>
<td>Maximilian Merz, Judith Ritsch, Christina Kunz, Barbara Wagner, Sandra Sauer, Dirk Hose, Thomas Moehler, Stefan Delorme, Hartmut Goldschmidt, Christian Zechmann, and Jens Hillengass</td>
</tr>
<tr>
<td>113</td>
<td>Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma</td>
<td>Sally E. Trabucco, Rachel M. Gerstein, Andrew M. Evens, James E. Bradner, Leonard D. Shultz, Dale L. Geiger, and Hong Zhang</td>
</tr>
<tr>
<td>134</td>
<td>The Novel IKK2 Inhibitor LY2409881 Potently Synergizes with Histone Deacetylase Inhibitors in Preclinical Models of Lymphoma through the Downregulation of NF-κB</td>
<td>Changshun Deng, Mark Lipstein, Richard Rodriguez, Xavier O. Jirau Serrano, Christine McIntosh, Wei-Yan Tsai, Andrew S. Wasmuth, Susan Jaken, and Owen A. O’Connor</td>
</tr>
<tr>
<td>146</td>
<td>CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin</td>
<td>Clara Gucerzoni, Valentina Fiori, Mario Terracciano, Maria Cristina Manara, Diego Moricoli, Michela Pasello, Mariika Scialendi, Giordano Nicoletti, Mara Gellini, Sabrina Dominici, Claudia Chiodoni, Pier Maria Formanati, Pier-Luigi Lollini, Mario P. Colombo, Piero Picci, Maurizio Cianfriglia, Mauro Magnani, and Katia Scollandi</td>
</tr>
<tr>
<td>166</td>
<td>Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer</td>
<td>Ryohei Katayama, Yuka Kobayashi, Luc Friboulet, Elizabeth L. Lockerman, Sumie Koike, Alice T. Shaw, Jeffrey A. Engelmann, and Naoya Fujita</td>
</tr>
<tr>
<td>175</td>
<td>Development of a Prognostic Genetic Signature to Predict the Metastatic Risk Associated with Cutaneous Melanoma</td>
<td>Pedram Gerami, Robert W. Cook, Jeff Wilkinson, Maria C. Russell, Navneet Dhillon, Rodabe N. Amaria, Rene Gonzalez, Stephen Lyle, Clare E. Johnson, Kristen M. Oelschlagel, Gilchrist L. Jackson, Anthony J. Greisinger, Derek Maetzold, Keith A. Delman, David H. Lawson, and John F. Stone</td>
</tr>
<tr>
<td>184</td>
<td>Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups</td>
<td>Diana M. Merino, Adam Shlien, Anita Villani, Malgorzata Pienkowski, Stephen Mack, Vijay Ramaswamy, David Shih, Ruth Tatevossian, Ana Novokmet, Sanah Choufani, Rina Dvir, Myra Ben-Arush, Brent T. Harris, Eugene I. Hwang, Rishi Lulla, Stefan M. Pflister, Maria Isabel Achatz, Nada Jabadod, Jonathan L. Finlay, Rosanna Weksberg, Cynthia Hawkins, Michael D. Taylor, Uri Tabori, David W. Ellison, Richard J. Gilbertson, and David Malkin</td>
</tr>
</tbody>
</table>
# Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>193</td>
<td>The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling</td>
<td>Chi-Pang Wen, Fanmao Zhang, Dong Liang, Christopher Wen, Jian Gu, Heath Skinner, Wong-Ho Chow, Yuanqing Ye, Xia Pu, Michelle A.T. Hildebrandt, Maosheng Huang, Chien-Hua Chen, Chao Agnes Hsiung, Min Kuang Tsai, Chwen Keng Tsao, Scott M. Lippman, and XiFeng Wu</td>
</tr>
<tr>
<td>201</td>
<td>Activation of IL6/IGFIR Confers Poor Prognosis of HBV-Related Hepatocellular Carcinoma through Induction of OCT4/NANOG Expression</td>
<td>Te-Sheng Chang, Yu-Chih Wu, Ching-Chi Chi, Wei-Chi Su, Pey-Jium Chang, Kam-Fai Lee, Tao-Hsin Tung, Jui Wang, Jun-Jen Liu, Shui-Yi Tung, Liang-Mou Kuo, Hong-Nerng Ho, Thai-Yen Ling, and Yen-Hua Huang</td>
</tr>
<tr>
<td>211</td>
<td>Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis</td>
<td>Qian Zhong, Hong-Ling Peng, Xia Zhao, Lin Zhang, and Wei-Ting Hwang</td>
</tr>
</tbody>
</table>

**LETTERS TO THE EDITOR**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>221</td>
<td>Diffusion-Weighted MRI for Lymphoma Staging—Letter</td>
<td>Hugo J.A. Adams and Thomas C. Kwee</td>
</tr>
<tr>
<td>222</td>
<td>Diffusion-Weighted MRI for Lymphoma Staging—Response</td>
<td>Marius E. Mayerhoefer and Markus Raderer</td>
</tr>
</tbody>
</table>

**ABOUT THE COVER**

The cover shows the results of an unsupervised two-dimensional hierarchical clustering analysis of the 5,000 most variable genes classifying breast tumors into ER⁺, HER2⁺, or triple-negative (ER⁻, PR⁻, HER2⁻) subtypes. The analysis was performed on 800 breast tumors obtained from the Karolinska Institutet, Sweden. The RAS gene expression signature was high in the triple-negative subtype and low in the ER⁺ subtype. For details, see the article by Di Cosimo and colleagues on page 49 of this issue.